首页 | 本学科首页   官方微博 | 高级检索  
     

莫西沙星对老年耐多药肺结核病的临床观察
引用本文:耿书军,刘建玲,宋韬,张向丛,高官聚. 莫西沙星对老年耐多药肺结核病的临床观察[J]. 临床肺科杂志, 2012, 17(6): 1068-1070
作者姓名:耿书军  刘建玲  宋韬  张向丛  高官聚
作者单位:石家庄,河北省胸科医院结核内科,河北,050041
摘    要:目的比较和评价含莫西沙星(MXFX)方案与含左氧氟沙星(LVFX)方案对老年耐多药肺结核病(MDR-PTB)的治疗效果及安全性。方法将80例老年痰菌阳性的MDR-PTB患者随机分成试验组(A组)40例及对照组(B组)40例,A组用含MXFX方案;B组用含LVFX方案,疗程结束时对两组患者进行比较。结果满3个月时痰菌阴转率A组为65%、B组为40%,两组对比差异有统计学意义,满18个月时A组及B组分别为77.5%、72.5%;疗程末影像吸收有效率A组72.5%,B组65%,空洞有效率分别为65%、52.5%;副作用A组30.0%,B组为37.5%。结论 MXFX对老年MDR-PTB的治疗是有效且安全的。

关 键 词:莫西沙星  结核  肺/药物疗法  抗多种药物性  老年人

A Clinical Observation of Moxifloxacin's Curative Effects on Senior Patients Troubled by Multi-drug Resistant Pulmonary Tuberculosis
GENG Shu-jun , LIU Jian-ling , SONG Tao , ZHANG Xiang-cong , GAO Guan-ju. A Clinical Observation of Moxifloxacin's Curative Effects on Senior Patients Troubled by Multi-drug Resistant Pulmonary Tuberculosis[J]. Journal of Clinical Pulmonary Medicine, 2012, 17(6): 1068-1070
Authors:GENG Shu-jun    LIU Jian-ling    SONG Tao    ZHANG Xiang-cong    GAO Guan-ju
Affiliation:Department of Internal Medicine,Hebei Provincial Chest Hospital,Shijiazhuang 050041,China
Abstract:Objective Compare and evaluate the curative effects and security of the MXFX solution and LVFX solution on senior patients troubled by multi-drug resistant pulmonary tuberculosis.Methods Randomly divide 80 MDR-PTB senior patients who are tubercule bacillus positive in sputum into experimental group(group A) of 40 cases and control group(group B) of 40 cases.The group A employs MXFX solution,while group B employs LVFX solution.Compare the two groups at the end of the treatment.Results After three months’treatment,sputum negative conversion rates of group A and group B are 65% and 40% respectively.The difference between the two groups is of statistical significance.After eighteen months’ treatment,the rates are 77.5% and 72.5% respectively.At the end of the treatment,the photographic absorptive effective rates are 72.5% and 65% respectively,and the void effective rates are 65% and 52.5% respectively.The side effect rates of the two groups are 30.0% and 37.5% respectively.Conclusions It is effective and safe to employ MXFX in the treatment of senior patients troubled by multi-drug resistant pulmonary tuberculosis.
Keywords:Moxifloxacin  tuberculosis  pulmonary/drug therapy  multi-drug resistance  senior patients
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号